References
  1. De Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang 2015; 109: 99-113
  2. Tiblad E, Kublickas M, Ajne G, Bui The Hung, Karlsson A, Ek S et al.Procedure related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther 2011; 30:266-273
  3. Moise KJ. Management of rhesus alloimmunization in pregnancy. Obstetr Gynecol 2008; 112: 164-176
  4. Urbaniak SJ. The scientific basis of antenatal prophylaxis. Br J Obstetr Gynecol 1998; 105:11-18
  5. Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing rhesus alloimmunization. The Cochrane Library 2009
  6. Clausen FB. Lessons learned from the implementation of non-invasive fetal RHD screening. Experts Review of Molecular Diagnostics 2018;5:423-431
  7. Davies J, Chant R, Simpson S, Powell R. Routine antenatal anti-D prophylaxis: is the protection adequate? Transfus Med 2011; 21: 421-426
  8. White SW, Cheng JC, Penova-Veselinovic B, Wang C, White M, Ingleby B et al. Single dose v two-dose antenatal anti-D prophylaxis: a randomized controlled trial. Medical Journal of Australia 2019; 16:261-265
  9. Koelewijn JM, Haas de M, Vrijkotte TGM, van der Schoot CE, Bonsel GJ. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 2009; 116: 1307-1314.
  10. Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J et al.BCSH for the use of anti-D immunoglobulin for the prevention of hemolytic disease of the newborn. Transf Med 2014;24:8-20
  11. Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 1986;51:117–121
  12. Tiblad E, Westgren M, Pasupathy D, Karlsson A, Wikman A. Consequences of being RhD immunized during pregnancy and how to optimize new prevention strategies. ACTA Obstetr Gynecol 2013; 92: 1079-1085
  13. MacKenzie IZ, Roseman F, Findlay J, Thompson K, Jackson E, Scott J, et al. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D imunoglobulin. BJOG. 2006;113:97–101.
  14. Pilgrim H, Lloyd-Jones M, Reese A. Routine antenatal anti-D prophylaxis for RhD negative women; a systematic review and economic evaluation. Health Technol Asses 2009;13:1-103
  15. Taune Wikman A, Tiblad E, Karlsson A, Olsson ML, Westgren M. Non invasive single exon determination of fetal RHD in a routine screening programme in early pregnancy. Obstetr Gyneol 2012; 120:227-234
  16. Graviditetsimmunisering ”Pregnancy immunisation”2015.https://www.sfog.se/media/275278/argrapp74_omsl_inledn_lr_f_r_oinloggade.pdf
  17. Austin E, Bates S, de Silva M, Howarth D, Lubenko A, Rowley M, Scott M, Thomas E, White J, Williams M. Guidelines for the estimation of fetomaternal haemorrhage. Working party of the British Committee of Standards in Haematology, Transfusion Task Force.https://b-s-h.org.uk/media/15705/transfusion-austin-the-estimation-of-fetomaternal-haemorrhage.pdf
  18. Sebring ES, Polesky HS. Fetomaternal hemorrhage; incidence risk factors, time of occurrence and clinical effects. Transfusion 1990; 30:344-357.
  19. Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev. 1987;1:101–112.
  20. Lubusky M, Simetka O, Studnickova M, prochazka M, Ordeltova M, Vomackova K. Fetomaternal hemorrhage in normal vaginal delivery and in delivery by cesarian section. Transfusion 2012; 52:1977-1982
  21. World health Organisation. Prevention of Rh sensitization. Geneva; W.H.O Technical Report Series 468,1971:29.
  22. Medical Research Council Controlled trial of various anti-D dosages in suppression of rhesus sensitisation following pregnancy. Report to the Medical Research Council by the working party on the use of anti-D immunoglobulin for the prevention of the isoimmunization of Rh negative women during pregnancy. Br Med J 1974;ii75-80.
  23. https://www.fass.se/LIF/product?userType=0&nplId=20021115000215&docType=6&scrollPosition=785.3333129882812#pharmacodynamic
  24. Tiblad E, Wikman A, Rane A, Jansson Y, Westgren M. Pharmacokinetics of 250 g anti-D in the third trimester of pregnancy: an observational study. Acta Obstetr Gynecol 2012; 91: 587-592
Table 1 Characteristics of included women n=39